ContraVir Pharma Appoints CFO

ContraVir Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, has named John Cavan as chief financial officer. Mr. Cavan had served as the company’s interim CFO since January 2016.

“John is an accomplished executive with significant financial and operational expertise within the biotechnology industry, and we are pleased to have him assume this key executive role,” said James Sapirstein, chief executive officer, ContraVir. “We expect John will continue building upon the value he’s brought to ContraVir, taking a lead role in supporting our growth trajectory as we seek to maximize the value of our pipeline and enhance our position within the antiviral industry.”

Mr. Cavan brings more than 20 years of financial management experience in both public and private companies. Prior to joining ContraVir as interim chief financial officer, Mr. Cavan was a consultant with The Pine Hill Group where he was instrumental in completing several financial transactions, including initial public offerings, business combinations and strategic transactions.